In a recent development, Novo Nordisk has reported that a substantial number of counterfeit units of their diabetes treatment drug Ozempic have been discovered circulating outside of the authorized supply chain in the United States. The US health regulatory authorities took action and seized the counterfeit injections on April 9th, initiating an investigation into the matter.
The increasing demand for Novo's Ozempic, scientifically known as semaglutide, has raised concerns regarding the potential presence of unregulated, compounded, and counterfeit medications in the market. Notably, Novo's weight-loss drug Wegovy contains the same active ingredient as Ozempic.
While the investigation unfolds, in-depth examinations such as extensive visual inspections and chemical tests are being conducted on the confiscated counterfeit product. According to the US Food and Drug Administration, neither they nor Novo Nordisk currently possess information regarding the authenticity, quality, or safety of the fraudulent drugs in question.
In response to this unsettling discovery, Novo Nordisk has issued a recommendation for retail pharmacies to procure Ozempic injections exclusively from authorized distributors. Furthermore, patients are advised to thoroughly examine their product for any indications of counterfeiting before administering the medication. The company stresses the importance of vigilance and urges caution to safeguard against potential risks associated with counterfeit drugs.